FDA Grants Avelumab Priority Review for Metastatic Urothelial Carcinoma

February 28, 2017 – The FDA has granted a priority review to a biologics license application (BLA) for avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) whose disease has progressed after platinum-based therapy, according to Merck KGaA and Pfizer, the codevelopers of the PD-L1 inhibitor. The priority review is based on data from the JAVELIN international development program of avelumab. In the JAVELIN … (leggi tutto)